Because inhibition of AR, as seen in the 5α-reductase studies, can reduce the risk of prostate cancer, we hypothesized that the reduced risk of prostate cancer associated with warfarin usage could be mediated, at least in part, by its inhibitory effects on AR signaling. The gene discussed is AR; the disease is prostate carcinoma.